CN115089648A - Sanitary wet tissue for preventing/treating haemorrhoids and preparation method thereof - Google Patents
Sanitary wet tissue for preventing/treating haemorrhoids and preparation method thereof Download PDFInfo
- Publication number
- CN115089648A CN115089648A CN202210781531.3A CN202210781531A CN115089648A CN 115089648 A CN115089648 A CN 115089648A CN 202210781531 A CN202210781531 A CN 202210781531A CN 115089648 A CN115089648 A CN 115089648A
- Authority
- CN
- China
- Prior art keywords
- wet tissue
- sanitary
- extract
- preventing
- humectant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000014617 hemorrhoid Diseases 0.000 title claims abstract description 53
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 239000000284 extract Substances 0.000 claims abstract description 74
- 239000000654 additive Substances 0.000 claims abstract description 36
- 230000000996 additive effect Effects 0.000 claims abstract description 36
- 239000002994 raw material Substances 0.000 claims abstract description 18
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 17
- 241001116757 Pyrrosia lingua Species 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 14
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 12
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229940116229 borneol Drugs 0.000 claims abstract description 12
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000002131 composite material Substances 0.000 claims abstract description 9
- 238000004659 sterilization and disinfection Methods 0.000 claims abstract description 8
- 238000003756 stirring Methods 0.000 claims description 48
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 33
- 239000003906 humectant Substances 0.000 claims description 29
- 239000007788 liquid Substances 0.000 claims description 29
- 238000005303 weighing Methods 0.000 claims description 21
- 238000002156 mixing Methods 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 238000001514 detection method Methods 0.000 claims description 13
- 239000000341 volatile oil Substances 0.000 claims description 12
- 239000008213 purified water Substances 0.000 claims description 11
- 241000628997 Flos Species 0.000 claims description 9
- 241000208681 Hamamelis virginiana Species 0.000 claims description 9
- 235000011399 aloe vera Nutrition 0.000 claims description 9
- 244000144927 Aloe barbadensis Species 0.000 claims description 8
- 235000002961 Aloe barbadensis Nutrition 0.000 claims description 8
- 230000032683 aging Effects 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 235000005979 Citrus limon Nutrition 0.000 claims description 7
- 244000131522 Citrus pyriformis Species 0.000 claims description 7
- 229920001131 Pulp (paper) Polymers 0.000 claims description 7
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 7
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical group [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 7
- 230000009965 odorless effect Effects 0.000 claims description 7
- 238000004806 packaging method and process Methods 0.000 claims description 7
- 239000003755 preservative agent Substances 0.000 claims description 7
- 230000002335 preservative effect Effects 0.000 claims description 7
- 238000002791 soaking Methods 0.000 claims description 7
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 6
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims description 3
- 240000007263 Pinus koraiensis Species 0.000 claims description 3
- 235000011615 Pinus koraiensis Nutrition 0.000 claims description 3
- 230000002421 anti-septic effect Effects 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Polymers CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 claims description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 2
- 244000178870 Lavandula angustifolia Species 0.000 claims description 2
- 235000010663 Lavandula angustifolia Nutrition 0.000 claims description 2
- 229920002413 Polyhexanide Polymers 0.000 claims description 2
- 229960001927 cetylpyridinium chloride Drugs 0.000 claims description 2
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 claims description 2
- 238000005520 cutting process Methods 0.000 claims description 2
- 239000001102 lavandula vera Substances 0.000 claims description 2
- 235000018219 lavender Nutrition 0.000 claims description 2
- 229960005323 phenoxyethanol Drugs 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 2
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 claims 1
- 229940035437 1,3-propanediol Drugs 0.000 claims 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 claims 1
- 208000024891 symptom Diseases 0.000 abstract description 12
- 206010061218 Inflammation Diseases 0.000 abstract description 9
- 241000205585 Aquilegia canadensis Species 0.000 abstract description 8
- 241000112528 Ligusticum striatum Species 0.000 abstract description 6
- 230000007794 irritation Effects 0.000 abstract description 5
- 241000208680 Hamamelis mollis Species 0.000 abstract description 4
- 230000006870 function Effects 0.000 abstract description 4
- 238000011031 large-scale manufacturing process Methods 0.000 abstract description 4
- 230000008569 process Effects 0.000 abstract description 4
- 229940118846 witch hazel Drugs 0.000 abstract description 4
- 230000001954 sterilising effect Effects 0.000 abstract description 3
- 235000014104 aloe vera supplement Nutrition 0.000 abstract description 2
- 230000036592 analgesia Effects 0.000 abstract description 2
- 240000005020 Acaciella glauca Species 0.000 abstract 1
- 235000018782 Dacrydium cupressinum Nutrition 0.000 abstract 1
- 235000013697 Pinus resinosa Nutrition 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 105
- 230000000694 effects Effects 0.000 description 32
- 238000012360 testing method Methods 0.000 description 32
- 239000000243 solution Substances 0.000 description 26
- 230000008961 swelling Effects 0.000 description 20
- 206010042674 Swelling Diseases 0.000 description 19
- 206010015150 Erythema Diseases 0.000 description 16
- 208000002193 Pain Diseases 0.000 description 13
- 206010030113 Oedema Diseases 0.000 description 12
- 241000700159 Rattus Species 0.000 description 12
- 235000011187 glycerol Nutrition 0.000 description 12
- 230000036407 pain Effects 0.000 description 12
- 208000000114 Pain Threshold Diseases 0.000 description 11
- 210000000436 anus Anatomy 0.000 description 11
- 230000037040 pain threshold Effects 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 7
- 235000011613 Pinus brutia Nutrition 0.000 description 7
- 241000018646 Pinus brutia Species 0.000 description 7
- 231100000321 erythema Toxicity 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 6
- 208000003251 Pruritus Diseases 0.000 description 6
- 241000191967 Staphylococcus aureus Species 0.000 description 6
- 230000003385 bacteriostatic effect Effects 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 241000700198 Cavia Species 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- ZOJBYZNEUISWFT-UHFFFAOYSA-N allyl isothiocyanate Chemical compound C=CCN=C=S ZOJBYZNEUISWFT-UHFFFAOYSA-N 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 230000013872 defecation Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 239000008164 mustard oil Substances 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 241000700199 Cavia porcellus Species 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000011056 performance test Methods 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 3
- 206010068286 Anorectal discomfort Diseases 0.000 description 3
- 239000001263 FEMA 3042 Substances 0.000 description 3
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 3
- 241000025505 Pyrrosia Species 0.000 description 3
- 206010040880 Skin irritation Diseases 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 239000000306 component Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000002085 irritant Substances 0.000 description 3
- 231100000021 irritant Toxicity 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000000419 plant extract Substances 0.000 description 3
- 230000001603 reducing effect Effects 0.000 description 3
- 229930004725 sesquiterpene Natural products 0.000 description 3
- 231100000475 skin irritation Toxicity 0.000 description 3
- 230000036556 skin irritation Effects 0.000 description 3
- 235000015523 tannic acid Nutrition 0.000 description 3
- 229920002258 tannic acid Polymers 0.000 description 3
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 3
- 229940033123 tannic acid Drugs 0.000 description 3
- 244000035851 Chrysanthemum leucanthemum Species 0.000 description 2
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 2
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 2
- 206010010726 Conjunctival oedema Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical group NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 241000283977 Oryctolagus Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 206010036772 Proctalgia Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 229940069521 aloe extract Drugs 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000006081 fluorescent whitening agent Substances 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000000554 iris Anatomy 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 230000009191 jumping Effects 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 230000001617 migratory effect Effects 0.000 description 2
- 231100000286 mucous membrane, eye irritation or corrosion testing Toxicity 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- NFLGAXVYCFJBMK-RKDXNWHRSA-N (+)-isomenthone Natural products CC(C)[C@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-RKDXNWHRSA-N 0.000 description 1
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- XFZJEEAOWLFHDH-UHFFFAOYSA-N (2R,2'R,3R,3'R,4R)-3,3',4',5,7-Pentahydroxyflavan(48)-3,3',4',5,7-pentahydroxyflavan Natural products C=12OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C(O)C=C(O)C=1C(C1=C(O)C=C(O)C=C1O1)C(O)C1C1=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UHFFFAOYSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 206010007027 Calculus urinary Diseases 0.000 description 1
- 241000219321 Caryophyllaceae Species 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000028006 Corneal injury Diseases 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 206010015946 Eye irritation Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 241000208690 Hamamelis Species 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000229179 Ledebouriella Species 0.000 description 1
- 244000011376 Leptospermum laevigatum Species 0.000 description 1
- 235000017865 Leptospermum laevigatum Nutrition 0.000 description 1
- NFLGAXVYCFJBMK-UHFFFAOYSA-N Menthone Chemical compound CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 description 1
- 241001448624 Miliaria Species 0.000 description 1
- 241000219926 Myrtaceae Species 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241000222640 Polyporus Species 0.000 description 1
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 description 1
- MOJZMWJRUKIQGL-FWCKPOPSSA-N Procyanidin C2 Natural products O[C@@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c([C@H]3[C@H](O)[C@@H](c4cc(O)c(O)cc4)Oc4c3c(O)cc(O)c4)c(O)cc(O)c2[C@@H]1c1c(O)cc(O)c2c1O[C@@H]([C@H](O)C2)c1cc(O)c(O)cc1 MOJZMWJRUKIQGL-FWCKPOPSSA-N 0.000 description 1
- 208000015815 Rectal disease Diseases 0.000 description 1
- 240000003152 Rhus chinensis Species 0.000 description 1
- 235000014220 Rhus chinensis Nutrition 0.000 description 1
- 244000007853 Sarothamnus scoparius Species 0.000 description 1
- 206010040849 Skin fissures Diseases 0.000 description 1
- 206010058679 Skin oedema Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 102000003566 TRPV1 Human genes 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 101150016206 Trpv1 gene Proteins 0.000 description 1
- 208000009911 Urinary Calculi Diseases 0.000 description 1
- 206010046996 Varicose vein Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000008358 core component Substances 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 231100000013 eye irritation Toxicity 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000011597 hartley guinea pig Methods 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000008932 jinhong Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229930007503 menthone Natural products 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- HGVVOUNEGQIPMS-UHFFFAOYSA-N procyanidin Chemical compound O1C2=CC(O)=CC(O)=C2C(O)C(O)C1(C=1C=C(O)C(O)=CC=1)OC1CC2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 HGVVOUNEGQIPMS-UHFFFAOYSA-N 0.000 description 1
- 229920002414 procyanidin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- -1 sesquiterpene ketone Chemical class 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 235000021259 spicy food Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000009602 toxicology test Methods 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
- A61K36/12—Filicopsida or Pteridopsida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0208—Tissues; Wipes; Patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9741—Pteridophyta [ferns]
- A61K8/9749—Filicopsida or Pteridopsida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Birds (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Insects & Arthropods (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Animal Husbandry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a sanitary wet tissue for preventing/treating hemorrhoids and a preparation method thereof, belonging to the technical field of sanitary products. The sanitary wet tissue is prepared from a wet tissue carrier and a wet tissue additive solution; the wet tissue additive solution comprises the following preparation raw materials in parts by weight: 5-15 parts of witch hazel extract, 0.05-5 parts of aloe vera extract, 0.05-5 parts of honeysuckle extract, 0.01-0.1 part of gallnut extract, 0.05-1 part of ligusticum wallichii extract, 0.1-2 parts of red pine composite refined extract, 0.05-1 part of pyrrosia lingua and 0.01-0.1 part of borneol. The sanitary wet tissue provided by the invention not only has the functions of analgesia, anti-inflammation, detumescence and sterilization, but also can better relieve the symptoms of hemorrhoids; meanwhile, the sanitary wet tissue has higher safety and low use irritation. The preparation method of the sanitary wet tissue provided by the invention has the advantages of simple and efficient process, safe and easily-obtained raw material sources, and is very suitable for large-scale production and application.
Description
Technical Field
The invention belongs to the technical field of hygienic products, and particularly relates to a hygienic wet tissue for preventing/treating hemorrhoids and a preparation method thereof.
Background
Hemorrhoids are the most frequent diseases in anorectal diseases and account for about 90 percent of the total number of patients. According to incomplete statistics, the total number of patients with hemorrhoids reaches 5 hundred million. Among patients with hemorrhoids, the elderly, the people who sit for a long time, drivers, pregnant women and the like are high risk groups of hemorrhoids; in the aspect of disease causes, spicy food, sedentary sitting, constipation and the like are high risk factors of hemorrhoids; in the aspect of disease symptoms, pain, pruritus and hematochezia are three main symptoms of hemorrhoids.
The traditional treatment method of the haemorrhoids comprises drug treatment and operation treatment, the first choice of drug treatment is for haemorrhoids with slight symptoms, common drugs comprise lotion, ointment, suppository and the like for external use, but the dosage forms are inconvenient to use, the ointment easily pollutes clothes, and the suppository and lotion patients have poor use experience, so that the patient compliance is poor. In contrast, the hemorrhoid wet tissue is gradually accepted by people in recent years, the hemorrhoid wet tissue can be used at any time, the hemorrhoid symptom can be relieved, the anus can be kept sanitary after defecation, the operation is convenient and rapid, and the compliance of patients is high. Therefore, hemorrhoid wet tissues have been widely studied and widely used in practice.
Patent document CN106265243A discloses an additive solution for sanitary wet tissues for preventing/treating hemorrhoids, and a preparation method and an application thereof, wherein the additive solution comprises a compound plant extract, an anti-allergy agent, a skin-moistening agent, a pH regulator, a preservative and water, the compound plant extract is a witch hazel extract, an aloe extract, a gallnut extract, a honeysuckle extract, a wild chrysanthemum extract and a borneol extract, the added compound plant extract has the functions of astringing, anti-inflammation, cooling, soothing and auxiliary anti-allergy on skin, and the satisfaction rate of the prepared sanitary wet tissues for preventing/treating hemorrhoids in relieving perianal irritation reaches more than 90%, and the effect is remarkable. The sanitary wet tissue for preventing/treating hemorrhoids mainly has cleaning and relieving effects, is used for cleaning the perianal area to keep the anus sanitary after defecation, and has no obvious effect on symptoms such as pain, pruritus, hemafecia and the like caused by hemorrhoids.
Patent document CN109833412A discloses a hemorrhoid wet towel, wherein the liquid for adding the wet towel is prepared from nine Chinese medicinal materials of astragalus root, ledebouriella root, witch hazel, aloe, honeysuckle flower, borneol, camphor, menthol and wild chrysanthemum oil through the processes of ultrahigh pressure extraction, alcohol precipitation, ultrafiltration and the like, the prepared hemorrhoid wet towel has a sterilization rate of 90.7% for staphylococcus aureus and 77.4% for escherichia coli, 17.8% of patients do not get better after clinical trial, and 4.4% of patients have local erythema and edema. The hemorrhoid wet tissue is complex in preparation process, is not suitable for industrial large-scale production, and needs to further improve the effectiveness and safety of the product.
Therefore, the existing sanitary wet tissue has single function, is generally only used for cleaning after defecation, has insignificant effect on relieving the hemorrhoid symptom, and cannot give consideration to effectiveness and safety comfort at the same time, so that the development of the sanitary wet tissue which can better relieve the hemorrhoid symptom and has high safety comfort is urgently needed.
Disclosure of Invention
In order to solve the defects of the prior art, the invention aims to provide the sanitary wet tissue for preventing/treating the hemorrhoids, which not only has the functions of easing pain, resisting inflammation, reducing swelling and sterilizing, but also can better relieve the symptoms of the hemorrhoids; the sanitary wet tissue also has higher safety and low irritation in use.
The invention also aims to provide the preparation method of the sanitary wet tissue, which has the advantages of simple and efficient preparation process, safe and easily obtained raw material sources and suitability for large-scale production and application.
In order to achieve the purpose, the invention adopts the following technical scheme:
a sanitary wet tissue for preventing/treating haemorrhoids is prepared from a wet tissue carrier and a wet tissue additive solution, wherein the wet tissue additive solution comprises the following preparation raw materials in parts by weight:
the hamamelis extract mainly contains tannin, gallic acid, catechin, procyanidin, flavonoid, essential oil, etc., and has good antiinflammatory, antibacterial, antiallergic and astringent effects. The witch hazel extract contains tannic acid which has a strong anti-inflammatory effect and is beneficial to treating skin inflammation, and is also an effective skin astringent, wherein the tannic acid and protein are subjected to condensation reaction in modes of hydrophobic bonds, hydrogen bonds and the like, so that people feel skin tightening and contraction, namely astringency.
The aloe extract has natural effects of diminishing inflammation, preserving moisture and locking water, can form a smooth moisture absorption film on the surface of skin, improves the gorgeous feeling and the flexibility of a formula under the condition of not increasing the viscosity, has a better relieving effect due to the rich polysaccharide, and has better cooling, relieving, moisture-preserving, repairing and anti-oxidation effects.
Galla chinensis extract contains large amount of tannic acid, and can coagulate local tissue protein of skin, mucosa, ulcer, etc. to achieve astringent effect, and accelerate blood coagulation to achieve hemostatic effect; the gallnut extract also has good antioxidation and bacteriostasis effects, and has inhibition effects on staphylococcus aureus, dysentery bacillus freundii, cholera suis and escherichia coli.
Honeysuckle is known as a good medicine for clearing heat and removing toxicity from old times, and the honeysuckle extract contains chlorogenic acid as an active ingredient, so that the honeysuckle extract not only has the effects of resisting inflammation, clearing heat, resisting oxidation and aging, but also has the effects of preventing corrosion, removing miliaria, relieving itching and preventing dry, rough and chapped skin.
The ligusticum wallichii is a common traditional Chinese medicine for promoting blood circulation and removing blood stasis, can better improve local congestion, varicosity or tissue hyperplasia of hemorrhoid diseases, and the ligusticum wallichii extract mainly contains volatile oil, alkaloid, phenolic acid, phenolphthalein and other substances; the ligusticum wallichii also has good bacteriostatic activity and has obvious inhibition effect on escherichia coli and staphylococcus aureus.
The core component of the composite refined extract of the pine and red plum is the pine and red plum, which belongs to the genus of caryophyllaceae, namely the genus of thinleaf, namely the family Myrtaceae, namely the Australian tea tree with broom leaf, and the pine and red plum is bright in color, is rich in essential oil mainly comprising sesquiterpene, sesquiterpene alcohol and sesquiterpene ketone components, and is mainly wild. Modern pharmacological tests show that the compound extract of the red plum has the effects of inhibiting TRPV1 and NO generation and histamine signal passage through the synergistic effect of the red plum, the tetrandra root, the lotus flower and other components, and has strong inhibition effect on local skin pricking pain, erythema and telangiectasia caused by external irritants and inflammations.
Borneolum has effects of inducing resuscitation, refreshing mind, clearing heat and relieving pain, and can be used for treating block pattern of coma, conjunctival congestion, swelling and pain, sore throat, aphtha, pyocutaneous disease, swelling and pain, and unhealing ulcer. Modern pharmacological research shows that borneol has relatively small stimulation to sensory nerve, certain pain relieving and mild antiseptic effect, and relatively high concentration (0.5%) of borneol has relatively high inhibition effect on staphylococcus, streptococcus, pneumococci, colibacillus, some pathogenic dermatophyte, etc.
Pyrrosia lingua is dry leaf of Pyrrosia cottage or Pyrrosia officinali (Christ) Ching of Polyporus, and has sweet and bitter taste and slightly cold nature. Modern pharmacological studies show that the pyrrosia lingua has the effects of inducing diuresis and removing urinary calculus, inhibiting bacteria, relieving cough, resisting inflammation and virus and enhancing immunity, and can induce diuresis and treat stranguria, clear away the lung-heat and relieve cough, and cool blood and stop bleeding. In clinic, pyrrosia lingua is commonly used for urinary system diseases.
As further optimization of the technical scheme of the invention, the wet tissue additive solution comprises the following preparation raw materials in parts by weight:
as a further preference of the technical scheme of the invention, the wet tissue carrier is original wood pulp paper capable of being dispersed; it meets sloshing box decomposition test and toilet bowl and sewer cleaning test in the guidelines for evaluation of flushable performance of disposable nonwoven products (fourth edition).
As a further preferable mode of the technical solution of the present invention, the raw materials for preparing the wet tissue additive solution further include one or more of an aromatic, a solubilizer, a humectant, a preservative, or purified water.
In a further preferred embodiment of the present invention, the amounts of the aromatic, the solubilizer, the humectant, the preservative, and the purified water are 0.01 to 0.05 part, 0.1 to 1 part, 3 to 10 parts, 0.01 to 0.15 part, and 60 to 90 parts, respectively, by weight.
As a further preferred embodiment of the present invention, the aromatic is one or two selected from lemon essential oil and lavender essential oil.
As a further preferable mode of the present invention, the solubilizer is a water-soluble odorless freshener, i.e., menthone glycerol ketal.
As a further preferred embodiment of the present invention, the humectant is selected from one or more of 1, 3-propylene glycol, glycerin and butylene glycol.
As a further preferred embodiment of the present invention, the preservative is selected from one or more of benzalkonium chloride, polyhexamethylene biguanide, cetylpyridinium chloride and phenoxyethanol.
Meanwhile, the invention also provides a preparation method of the sanitary wet tissue for preventing/treating hemorrhoids, which comprises the following steps:
(1) sequentially weighing Hamamelis virginiana extract, Aloe barbadensis extract, Galla chinensis extract, flos Lonicerae extract, rhizoma Ligustici Chuanxiong extract, composite refined extract of Pinus koraiensis, antiseptic, and purified water, and adding and stirring; then, adding the first part of humectant, uniformly stirring again, then adding the crushed pyrrosia lingua, and uniformly stirring to obtain a phase A;
(2) weighing borneol and adding the borneol into the second part of the humectant, and stirring until the borneol and the humectant are dissolved together to obtain a phase B;
(3) weighing aromatic and solubilizer, mixing and stirring to obtain phase C;
(4) mixing the phase B obtained in the step (2) with the phase C obtained in the step (3), adding a third part of humectant, stirring uniformly, slowly adding the phase A obtained in the step (1), and stirring uniformly again to obtain a feed liquid; aging the obtained feed liquid, and obtaining the wet tissue additive liquid after the detection is qualified;
(5) soaking the wet tissue carrier subjected to cutting, sterilization and disinfection treatment in the wet tissue additive solution obtained in the step (4), and controlling the liquid content to be 2-3 wt%; and finally, folding, and carrying out aseptic sealed packaging to obtain the sanitary wet tissue.
Compared with the prior art, the invention has the following beneficial effects:
(1) the sanitary wet tissue has a strong bacteriostatic action, the average bacteriostatic rate of the sanitary wet tissue on staphylococcus aureus and escherichia coli is up to 100%, and toxicological tests show that the sanitary wet tissue has no irritation, can be used for a long time and has high safety.
(2) Compared with the traditional sanitary wet tissue, pharmacological tests show that the sanitary wet tissue has better effects of resisting inflammation, easing pain, reducing swelling and stopping bleeding; clinical trial results show that the wet tissue has good curative effect on relieving the symptoms of the hemorrhoids, has no stimulation and allergy phenomena in the using process, is mild in product property, convenient and comfortable to use, and is very worthy of popularization and application in patients with the hemorrhoids.
(3) The preparation process of the sanitary wet tissue is simple and efficient, the raw materials are safe and easily available, the sanitary wet tissue is suitable for large-scale production and application, and the product value is high.
(4) The raw material types are optimized, and Hamamelis virginiana extract, aloe barbadensis extract, Chinese gall extract, honeysuckle extract, ligusticum wallichii extract, composite extract of pine and red plum and pyrrosia lingua are selected as main raw materials; the pine and red plum compound extract and the pyrrosia lingua are creatively used in the hemorrhoid sanitary wet tissue for the inventor, the pine and red plum compound extract has the effects of better detumescence, analgesia and itching relieving, and the pyrrosia lingua has the effects of promoting wound healing and resisting inflammation, and the pine and red plum compound extract and the pyrrosia lingua are matched with other raw materials to achieve the very good effects of detumescence and prevention/treatment of hemorrhoid.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is further described in detail with reference to the following embodiments. Of course, the specific embodiments described herein are merely illustrative of the invention and are not intended to be limiting.
Although the steps in the present invention are arranged by using reference numbers, the order of the steps is not limited, and the relative order of the steps can be adjusted unless the order of the steps is explicitly stated or other steps are required for the execution of a certain step. It is to be understood that the term "and/or" as used herein refers to and encompasses any and all possible combinations of one or more of the associated listed items.
Wherein, the pyrrosia lingua used in the invention is pyrrosia petiolata; meanwhile, purchase information of part of the material is as follows
Hamamelis virginiana extract: wuhan Ling Benke Techni Co., Ltd;
aloe vera extract: beijing Oriental vast Sen Biotech, Inc.;
gallnut extract: wufeng akang biotechnology limited;
and (3) honeysuckle extract: beijing Oriental vast Sen Biotech, Inc.; and (3) ligusticum wallichii extract: hongyu Chinese herbal pieces limited of Bozhou city;
compound refined extract of Pinus koraiensis (EneCooothe-MIX-Manuka): guangzhou Galen Biotechnology, Inc.;
borneol: yunnan Linyuan spices Ltd.
The rest raw materials in the invention are purchased from market sources unless otherwise specified.
Example 1
A sanitary wet tissue for preventing/treating hemorrhoids is prepared from a wet tissue carrier and a wet tissue additive solution, wherein the wet tissue additive solution is prepared from the following raw materials:
in this embodiment, a method for preparing the sanitary wet tissue is further provided, which includes the following steps:
(1) sequentially weighing Hamamelis virginiana extract, Aloe barbadensis extract, Galla chinensis extract, flos Lonicerae extract, rhizoma Ligustici Chuanxiong extract, composite refined extract of folium Pini and HONGMEI, benzalkonium chloride, and purified water, adding one by one, and stirring; then, adding a first part of humectant (3/4 glycerol), uniformly stirring again, then adding the crushed pyrrosia lingua, and uniformly stirring to obtain a phase A;
(2) weighing Borneolum Syntheticum, adding into the second humectant (butanediol), and stirring to dissolve to obtain phase B;
(3) weighing lemon essential oil and water-soluble odorless freshener, heating, mixing, and stirring to obtain phase C;
(4) mixing the phase B obtained in the step (2) with the phase C obtained in the step (3), adding a third part of humectant (residual 1/4 glycerol), stirring uniformly, slowly adding the phase A obtained in the step (1), and stirring uniformly again to obtain a feed liquid; aging the obtained feed liquid, and obtaining the wet tissue additive liquid after the detection is qualified;
(5) soaking the original wood pulp paper which is cut, sterilized and disinfected into the wet tissue additive solution obtained in the step (4), and controlling the liquid content to be 2.5 wt%; and finally, folding, and carrying out aseptic sealed packaging to obtain the sanitary wet tissue.
Example 2
A sanitary wet tissue for preventing/treating hemorrhoids is prepared from a wet tissue carrier and a wet tissue additive solution, wherein the wet tissue additive solution is prepared from the following raw materials:
in this embodiment, a method for preparing the sanitary wet tissue is further provided, which includes the following steps:
(1) sequentially weighing Hamamelis virginiana extract, Aloe barbadensis extract, Galla chinensis extract, flos Lonicerae extract, rhizoma Ligustici Chuanxiong extract, composite refined extract of folium Pini and flos Pruni mume, benzalkonium chloride, and purified water, adding one by one, and stirring; then, adding a first part of humectant (3/4 glycerol), stirring uniformly again, then adding the pulverized pyrrosia lingua, and stirring uniformly to obtain phase A;
(2) weighing Borneolum Syntheticum, adding into the second humectant (butanediol), and stirring to dissolve to obtain phase B;
(3) weighing lemon essential oil and water-soluble odorless freshener, heating, mixing, and stirring to obtain phase C;
(4) mixing the phase B obtained in the step (2) and the phase C obtained in the step (3), adding a third part of humectant (residual 1/4 glycerin), stirring uniformly, slowly adding the phase A obtained in the step (1), and stirring uniformly again to obtain a feed liquid; aging the obtained feed liquid, and obtaining the wet tissue additive liquid after the detection is qualified;
(5) soaking the original wood pulp paper which is cut, sterilized and disinfected into the wet tissue additive solution obtained in the step (4), and controlling the liquid content to be 2.5 wt%; and finally, folding, and carrying out aseptic sealed packaging to obtain the sanitary wet tissue.
Example 3
A sanitary wet tissue for preventing/treating hemorrhoids is prepared from a wet tissue carrier and a wet tissue additive solution, wherein the wet tissue additive solution is prepared from the following raw materials:
in this embodiment, a method for preparing the sanitary wet tissue is further provided, which includes the following steps:
(1) sequentially weighing Hamamelis virginiana extract, Aloe barbadensis extract, Galla chinensis extract, flos Lonicerae extract, rhizoma Ligustici Chuanxiong extract, composite refined extract of folium Pini and flos Pruni mume, benzalkonium chloride, and purified water, adding one by one, and stirring; then, adding a first part of humectant (3/4 glycerol), uniformly stirring again, then adding the crushed pyrrosia lingua, and uniformly stirring to obtain a phase A;
(2) weighing Borneolum Syntheticum, adding into the second humectant (butanediol), and stirring to dissolve to obtain phase B;
(3) weighing lemon essential oil and water-soluble odorless freshener, heating, mixing, and stirring to obtain phase C;
(4) mixing the phase B obtained in the step (2) and the phase C obtained in the step (3), adding a third part of humectant (residual 1/4 glycerin), stirring uniformly, slowly adding the phase A obtained in the step (1), and stirring uniformly again to obtain a feed liquid; aging the obtained feed liquid, and obtaining the wet tissue additive liquid after the detection is qualified;
(5) soaking the original wood pulp paper which is cut, sterilized and disinfected and can be dispersed in the wet tissue additive solution obtained in the step (4), and controlling the liquid content to be 2.5 wt%; and finally, folding, and carrying out aseptic sealed packaging to obtain the sanitary wet tissue.
Comparative example 1
A sanitary wet tissue for preventing/treating hemorrhoids is prepared from a wet tissue carrier and a wet tissue additive solution, wherein the wet tissue additive solution is prepared from the following raw materials:
in this comparative example, there is also provided a method for preparing the above sanitary wet wipe, comprising the steps of:
(1) sequentially weighing Hamamelis virginiana extract, Aloe barbadensis extract, Galla chinensis extract, flos Lonicerae extract, rhizoma Ligustici Chuanxiong extract, composite refined extract of folium Pini and HONGMEI, benzalkonium chloride, and purified water, adding one by one, and stirring; then, adding a first part of humectant (3/4 glycerin), and uniformly stirring again to obtain a phase A;
(2) weighing Borneolum Syntheticum, adding into the second humectant (butanediol), and stirring to dissolve to obtain phase B;
(3) weighing lemon essential oil and water-soluble odorless freshener, heating, mixing, and stirring to obtain phase C;
(4) mixing the phase B obtained in the step (2) and the phase C obtained in the step (3), adding a third part of humectant (residual 1/4 glycerin), stirring uniformly, slowly adding the phase A obtained in the step (1), and stirring uniformly again to obtain a feed liquid; aging the obtained feed liquid, and obtaining the wet tissue additive liquid after the detection is qualified;
(5) soaking the original wood pulp paper which is cut, sterilized and disinfected into the wet tissue additive solution obtained in the step (4), and controlling the liquid content to be 2.5 wt%; and finally, folding, and carrying out aseptic sealed packaging to obtain the sanitary wet tissue.
Comparative example 2
A sanitary wet tissue for preventing/treating hemorrhoids is prepared from a wet tissue carrier and a wet tissue additive solution, wherein the wet tissue additive solution is prepared from the following raw materials:
in this comparative example, there is also provided a method for preparing the above sanitary wet wipe, comprising the steps of:
(1) sequentially weighing Hamamelis virginiana extract, Aloe barbadensis extract, Galla chinensis extract, flos Lonicerae extract, rhizoma Ligustici Chuanxiong extract, benzalkonium chloride, and purified water, adding one by one, and stirring; then, adding a first part of humectant (3/4 glycerol), uniformly stirring again, then adding the crushed pyrrosia lingua, and uniformly stirring to obtain a phase A;
(2) weighing Borneolum Syntheticum, adding into the second humectant (butanediol), and stirring to dissolve to obtain phase B;
(3) weighing lemon essential oil and water-soluble odorless freshener, heating, mixing, and stirring to obtain phase C;
(4) mixing the phase B obtained in the step (2) and the phase C obtained in the step (3), adding a third part of humectant (residual 1/4 glycerin), stirring uniformly, slowly adding the phase A obtained in the step (1), and stirring uniformly again to obtain a feed liquid; aging the obtained feed liquid, and obtaining the wet tissue additive liquid after the detection is qualified;
(5) soaking the original wood pulp paper which is cut, sterilized and disinfected into the wet tissue additive solution obtained in the step (4), and controlling the liquid content to be 2.5 wt%; and finally, folding, and carrying out aseptic sealed packaging to obtain the sanitary wet tissue.
Test example 1: product performance test
(1) Bacteriostatic performance test of product
The sanitary wet tissue prepared in the embodiment 1-3 is taken to perform the bacteriostatic performance test according to appendix C4 of GB 15979-2002 hygienic standard for disposable sanitary products, wherein the strains used in the test are staphylococcus aureus (ATCC6538) and escherichia coli (8099) provided by the general microbiological center of China Committee for culture Collection of microorganisms. The action time is 2min, the test temperature is 18-20 ℃, and the measured bacteriostasis rate is shown in the following table 1.
Table 1 bacteriostatic property test results of sanitary wet tissues
As can be seen from Table 1, the sanitary wet tissue prepared in the embodiment of the invention has an average bacteriostasis rate of 100% to Staphylococcus aureus and Escherichia coli after 2min action, and has a strong bacteriostasis effect.
(2) Testing other Properties of the product
The sanitary wet tissue prepared in example 1 is taken, the appearance, pH value and migratory fluorescent whitening agent of the product are detected according to GB/T27728 plus 2011 wet tissue, the microorganism index of the product is detected according to GB 15979 plus 2002 disposable sanitary article sanitary standard, and the detection result is shown in Table 2.
TABLE 2 Performance test results for other products of sanitary wet towel
The results show that the product appearance, the pH value, the migratory fluorescent whitening agent and the product microorganism indexes of the sanitary wet tissue prepared by the invention all meet the regulations.
Test example 2: toxicology test of products
(1) Multiple complete skin irritation test
The stock solution of the sanitary wet tissue prepared in example 1 is subjected to a plurality of complete skin irritation tests according to the disinfection technical specification (2002 edition) 2.3.3.3.3, the test animals are 3 Japanese white rabbits with big ear, the weight range is 2.0-2.5 kg, the skin erythema and edema conditions of the animals are observed after the test objects are smeared for 24 hours, and the skin conditions are observed and scored every day.
And (3) test results: the erythema score and the edema score of the rabbit after being smeared for 14 days are both 0, and the skin irritation strength of the sanitary wet tissue stock solution of the invention for multiple times is non-irritant according to the result evaluation regulation in disinfection technical specification (2002 edition) 2.3.3.3.3.
(2) Acute eye irritation test
The stock solution of the sanitary wet towel prepared in example 1 was subjected to an acute eye irritation test by scoring the acute irritation response of the cornea, iris and conjunctiva of the eyes of 3 japanese white rabbits according to the disinfection technical specification (2002 edition) 2.3.4, wherein the weight of the tested animals ranged from 2.0 to 2.5kg, and the "average score" of each animal in four aspects of corneal damage, iris damage, conjunctival congestion and conjunctival edema at three different observation times (24h, 48h and 72h) was calculated.
And (3) test results: the average score of the rabbits is 0, and the acute eye irritation strength of the stock solution of the sanitary wet tissue is non-irritant according to the result evaluation regulation in disinfection technical specification (2002 edition) 2.3.4.
Test example 3: pharmacodynamic test of the product
1. Purpose of the test
Pharmacological tests are utilized to research the anti-inflammatory, analgesic and detumescent effects of the sanitary wet tissue prepared by the invention.
2. Test method
2, 4-Dinitrochlorobenzene (DNCB) induced guinea pig dermatitis model is adopted to evaluate the anti-inflammatory effect of the sanitary wet tissue; the analgesic effect of the sanitary wet tissue is evaluated by adopting a mouse hot plate pain-causing method; the swelling reducing effect of the sanitary wet tissue is evaluated by adopting a rat anus swelling test caused by mustard oil.
3. Test materials
3.1 test article
The sanitary wet tissues obtained in example 1 of the present invention were set as sample a, the sanitary wet tissues obtained in comparative example 1 were set as sample b, and the sanitary wet tissues obtained in comparative example 2 were set as sample c.
3.2 control
The fresh-air wet tissue EDI pure water wet tissue (Jinhong leaf paper industry group Co., Ltd., specification: 160 mm. times.200 mm, 80 pieces/bag) was used as a control group.
4. Test methods and results
4.1 Effect on 2, 4-Dinitrochlorobenzene (DNCB) model of Guinea pig dermatitis
4.1.1 grouping and administration
40 common-grade Hartley guinea pigs are selected and randomly divided into a model group, a control group, a sample a group, a sample b group and a sample c group, wherein each group comprises 8 male and female halves. The skin of the same area on the right side of the back of each guinea pig group was depilated, the size was 3cm × 3cm, the exposed area was applied and pasted with 200 μ L of 2% DNCB solution, 5 hours later, the application and pasting were carried out with the control group wet wipes and the sample group wet wipes, and the skin condition was observed and scored 0.5 hours later after the administration, and the degree of red swelling inhibition was calculated.
4.1.2 detection criteria
The method for evaluating the recovery condition of the individual red swelling comprises the following steps:
the individual swelling recovery grade (erythema score after wet tissue application and edema score after wet tissue application) - (erythema score before wet tissue application and edema score before wet tissue application)
4.1.3 test results
All animals were observed for general condition without abnormality. After 5 hours of DNCB solution administration to each group of guinea pigs, erythema and edema appeared to varying degrees, indicating successful modeling of the guinea pig skin inflammation model. The grade of recovery from skin redness in guinea pigs is shown in table 3, wherein, the grade 1 is a slightly increased degree of redness; grade 0 is no change in the degree of redness and swelling; grade-1 is a slight improvement in the degree of redness and swelling; grade-2 is a marked improvement in the degree of redness and swelling.
TABLE 3 summary of skin erythema edema recovery
As can be seen from Table 3, the degree of cutaneous erythema edema in most of the guinea pigs in the control group was unchanged and slightly improved in only a small part compared to the model group; the skin erythema edema of the guinea pigs in the group a is improved to a great extent, and the skin erythema edema of the guinea pigs in the group b and the group c is improved to a certain extent, so that the sanitary wet tissue prepared by the invention has a good anti-inflammatory effect.
4.2 Effect on mouse Hot plate pain model
4.2.1 grouping and administration
The time required from putting each mouse on a hot plate at 55 ℃ until licking, kicking or jumping occurs is respectively measured, the time is used as a basic pain threshold value, 50 female SPF-grade Kunming mice with the pain threshold value of 5s-30s are selected and randomly divided into 5 groups, namely a model group, a control group, a sample a group, a sample b group and a sample c group, and 10 mice in each group are respectively selected.
The palms and toes of the four limbs of the mice in the control group and the mice in the sample group were uniformly wiped and applied with the corresponding wet tissues about 3 times, each time at an interval of 5 minutes. After the application is finished, respectively placing the mice of the model group, the control group and the sample group on a metal plate preheated to 55 ℃, and recording the time from the beginning of thermal stimulation to the occurrence of pain reactions of the mice such as foot licking, leg kicking or jumping and the like as a pain threshold value; the pain threshold of each animal was determined 3 times in duplicate and the average was taken as the pain threshold measurement for that animal.
4.2.2 detection index
The rate of increase of pain threshold in mice was measured using the following formula:
4.2.3 test results
The general condition observation of all animals has no abnormality, and the detection results are shown in Table 4. Compared with a model group, the control group and the sample group both increase the hot plate pain threshold of the mouse obviously, and the pain threshold growth rate of the sample group a is the highest and reaches 58.32 percent, so that the sanitary wet tissue prepared by the method has an obvious analgesic effect.
TABLE 4 summary of pain threshold values for each group of mice
| Group of | Number of animals | Basal pain threshold | Threshold of pain | Pain threshold growth rate (%) |
| Model set | 10 | 9.45±3.92 | 9.38±2.33 | - |
| Control group | 10 | 10.04±2.76 | 14.41±4.14 ** | 43.53 |
| Sample a group | 10 | 10.58±3.18 | 16.75±4.61 ** | 58.32 |
| Sample b group | 10 | 10.27±2.95 | 15.92±4.33 ** | 55.01 |
| Sample group c | 10 | 10.31±3.66 | 15.16±4.78 ** | 47.04 |
Note: p <0.05, P <0.01, compared to model group
4.3 Effect on mustard oil smeared rat anal edema model
4.3.1 grouping and administration
Selecting 50 SPF SD rats, randomly dividing into 5 groups, namely a model group, a control group, a sample a group, a sample b group and a sample c group, wherein each group comprises 10 rats with half of male and female. Each group of rats was inserted into the anus for 10s with a swab soaked with mustard oil, and an anal edema model was established. Rats in a control group and a sample group are applied for 1 time after 3 hours of model building, and are applied for one time after 5min of interval, and photos of anus swelling parts before and 10min after wet tissue application of rats in an administration group are taken and compared with the anus of rats in a model group.
4.3.2 detection index
The swelling area in the picture is measured, and the fading condition of the swelling area is evaluated according to the swelling inhibition rate, and the specific calculation formula is as follows:
4.3.3 test results
The general condition observation of all animals has no abnormality, and the detection results are shown in Table 5. After mustard oil is inserted into the anus of each group of rats, obvious swelling appears, which indicates that the molding is successful; compared with the model group, the control group can relieve the rat anal edema caused by the mustard oil to a certain extent, but has no significant difference compared with the model group; the sample group can obviously inhibit the anus swelling of the rat, so that the sanitary wet tissue prepared by the invention has an obvious detumescence effect.
TABLE 5 summary of anus swelling results for each group of rats
Note: p <0.05, P <0.01, compared to model group
Test example 4 clinical trial
30 volunteers aged 18-65 years and within 5 days in the acute stage of hemorrhoid and having obvious symptoms of anus pain, pruritus and anus discomfort (foreign body sensation or feeling of falling and swelling) are recruited, the wet tissue prepared in the embodiment 1 of the invention is used for wiping the anus once in the morning and evening every day, the anus is wiped by the wet tissue after defecation every time, the test is carried out for 15 days continuously, other traditional Chinese medicines and western medicines influencing the test effect are forbidden in the test period, the comfort, convenience, safety and effectiveness of the product are evaluated after the test is finished, and a questionnaire is filled.
After the trial is finished, questionnaire results are collected and counted, and the obtained conclusion is as follows:
evaluation result of ease of use: all subjects considered comfortable and convenient to use, and were particularly suitable for use after defecation.
Results of safety evaluation in use: no irritation or adverse reaction was observed after all the subjects had been used.
Using the effectiveness evaluation results: after all the testees use the anus pain, pruritus and anus discomfort phenomena are improved, 12 (40%) testees are obviously improved, 18 (60%) testees are slightly improved, and the total effective rate of the product is up to 100%.
Clinical trial results show that the wet tissue prepared by the invention has good curative effect on relieving the symptoms of the hemorrhoids, has no stimulation and allergy phenomena in the using process, is mild in product property, convenient and comfortable to use, and is very worthy of popularization and application in patients with the hemorrhoids.
The technical idea of the present invention is explained by the above embodiments, but the present invention is not limited to the above embodiments, that is, it does not mean that the present invention must be implemented depending on the above embodiments. It should be understood by those skilled in the art that any modifications of the present invention, equivalent substitutions of individual materials of the product of the present invention, and the addition of auxiliary components, selection of specific modes, etc., are within the scope and disclosure of the present invention.
Claims (10)
1. A sanitary wet tissue for preventing/treating hemorrhoids is prepared from a wet tissue carrier and a wet tissue additive solution, and is characterized in that the wet tissue additive solution comprises the following preparation raw materials in parts by weight:
2. the sanitary wet tissue for preventing/treating hemorrhoids as claimed in claim 1, wherein the wet tissue additive solution comprises the following preparation raw materials in parts by weight:
3. a sanitary wet wipe for the prevention/treatment of hemorrhoids as claimed in claim 1 or 2, wherein said wet wipe carrier is flushable virgin wood pulp paper.
4. The sanitary wet tissue for preventing/treating hemorrhoids as claimed in claim 1 or 2, wherein the additive solution for wet tissue is prepared from one or more of aromatic, solubilizer, humectant, preservative or purified water.
5. The sanitary wet towel for preventing/treating hemorrhoids as claimed in claim 4, wherein the amount of the aromatic, the solubilizer, the humectant, the preservative and the purified water is 0.01-0.05 part, 0.1-1 part, 3-10 parts, 0.01-0.15 part and 60-90 parts by weight respectively.
6. The sanitary wet wipe for preventing/treating hemorrhoids as claimed in claim 4 or 5, wherein the aromatic is one or two selected from lemon essential oil or lavender essential oil.
7. The sanitary napkin for preventing/treating hemorrhoids as claimed in claim 4 or 5, wherein the solubilizer is a water-soluble odorless freshener.
8. A sanitary wet wipe for the prevention/treatment of hemorrhoids as claimed in claim 4 or 5, characterized in that said humectant is selected from one or a mixture of more of 1, 3-propanediol, glycerol or butanediol.
9. The sanitary wet towel for preventing/treating hemorrhoids as claimed in claim 4 or 5, wherein the preservative is selected from benzalkonium chloride, polyhexamethylene biguanide, cetylpyridinium chloride or a mixture of one or more phenoxyethanol.
10. The method for preparing a sanitary wet wipe for preventing/treating hemorrhoids as claimed in any one of claims 1 to 9, comprising the steps of:
(1) sequentially weighing Hamamelis virginiana extract, Aloe barbadensis extract, Galla chinensis extract, flos Lonicerae extract, rhizoma Ligustici Chuanxiong extract, composite refined extract of Pinus koraiensis, antiseptic, and purified water, and adding and stirring; then, adding the first part of humectant, uniformly stirring again, then adding the crushed pyrrosia lingua, and uniformly stirring to obtain a phase A;
(2) weighing borneol and adding the borneol into the second part of the humectant, and stirring until the borneol and the humectant are dissolved together to obtain a phase B;
(3) weighing aromatic and solubilizer, mixing and stirring to obtain phase C;
(4) mixing the phase B obtained in the step (2) with the phase C obtained in the step (3), adding a third part of humectant, stirring uniformly, slowly adding the phase A obtained in the step (1), and stirring uniformly again to obtain a feed liquid; aging the obtained feed liquid, and obtaining the wet tissue additive liquid after the detection is qualified;
(5) soaking the wet tissue carrier subjected to cutting, sterilization and disinfection treatment in the wet tissue additive solution obtained in the step (4), and controlling the liquid content to be 2-3 wt%; and finally, folding, and carrying out aseptic sealed packaging to obtain the sanitary wet tissue.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210781531.3A CN115089648A (en) | 2022-07-04 | 2022-07-04 | Sanitary wet tissue for preventing/treating haemorrhoids and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210781531.3A CN115089648A (en) | 2022-07-04 | 2022-07-04 | Sanitary wet tissue for preventing/treating haemorrhoids and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115089648A true CN115089648A (en) | 2022-09-23 |
Family
ID=83296376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210781531.3A Pending CN115089648A (en) | 2022-07-04 | 2022-07-04 | Sanitary wet tissue for preventing/treating haemorrhoids and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115089648A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116509778A (en) * | 2023-03-29 | 2023-08-01 | 兰树化妆品股份有限公司 | Preparation method and test method of broom leaf Australian tea and fermented turmeric composition for relieving itching |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106265243A (en) * | 2016-08-19 | 2017-01-04 | 天津郁美净集团有限公司 | A kind of crissum wet tissue annex solution and its preparation method and application |
| CN113634011A (en) * | 2021-08-24 | 2021-11-12 | 伽能生物科技(上海)有限公司 | Production integrated system of red pruned pine and red pruned refined extract composition, red pruned pine and red pruned refined extract composition and preparation method thereof |
-
2022
- 2022-07-04 CN CN202210781531.3A patent/CN115089648A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106265243A (en) * | 2016-08-19 | 2017-01-04 | 天津郁美净集团有限公司 | A kind of crissum wet tissue annex solution and its preparation method and application |
| CN113634011A (en) * | 2021-08-24 | 2021-11-12 | 伽能生物科技(上海)有限公司 | Production integrated system of red pruned pine and red pruned refined extract composition, red pruned pine and red pruned refined extract composition and preparation method thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116509778A (en) * | 2023-03-29 | 2023-08-01 | 兰树化妆品股份有限公司 | Preparation method and test method of broom leaf Australian tea and fermented turmeric composition for relieving itching |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109078165B (en) | Composition for nursing female private parts and preparation method and application thereof | |
| CN104940122B (en) | A kind of leave Feminine care solution and preparation method thereof | |
| CN102342993B (en) | Anti-sensitization and restoration external preparation for skin | |
| CN104983616B (en) | A kind of body lotion and preparation method thereof | |
| WO2011026267A1 (en) | Antiphlogistic, antioncotic and analgesic chinese herbal composition,preparative method and usage thereof | |
| KR20090129490A (en) | Extract of trigonella foenum-graecum | |
| US20130108599A1 (en) | Herbal Vaginal Compositions | |
| CN111202822A (en) | Gynecological external antibacterial spray and preparation method thereof | |
| CN106266384A (en) | A kind of plant ointment preventing and treating infant diaper rash and preparation method thereof | |
| CN113081928A (en) | Plant bacteriostatic gel and preparation method and application thereof | |
| WO2017093788A1 (en) | An anti fissure herbal composition for targeting fissure and method of synthesizing the same | |
| Widowati et al. | The use of betel (Piper betle) leaves for maintaining the health of women and children at various ethnic groups in Indonesia | |
| CN111759885A (en) | Sophora flavescens composition, sophora flavescens gel and preparation method thereof | |
| OA et al. | Preliminary study of effectiveness of Aloe vera in scabies treatment | |
| EP2985029A1 (en) | External-use medicament for cleaning and care of the ovaries, vagina and vulva | |
| CN111437225A (en) | Hemostatic, granulation-promoting and antibacterial composition and application thereof | |
| CN115089648A (en) | Sanitary wet tissue for preventing/treating haemorrhoids and preparation method thereof | |
| CN104116681A (en) | Hairdressing bath agent and preparation method thereof | |
| CN104306841B (en) | A kind of Chinese medicinal lotion for treating gynaecological imflammation, scytitis, pruritus | |
| CN105943666B (en) | Composition for nursing sensitive skin of infant and preparation method thereof | |
| CN110339249B (en) | Traditional Chinese medicine composition for treating hemorrhoids and anal fissure as well as preparation method and application thereof | |
| CN115569093B (en) | Infant dampness-dispelling skin-care cream with antibacterial effect and preparation method thereof | |
| CN106344460A (en) | Special moisturizing and acne-removing face cream for acne-prone skin and preparation method thereof | |
| CN109602868A (en) | Plant essence liquid and preparation method thereof and sanitary napkin application | |
| CN111904887B (en) | Skin hygiene care composition and application thereof in paper diapers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |